173 related articles for article (PubMed ID: 12695120)
1. Humanization of the anti-CD18 antibody 6.7: an unexpected effect of a framework residue in binding to antigen.
Caldas C; Coelho V; Kalil J; Moro AM; Maranhão AQ; Brígido MM
Mol Immunol; 2003 May; 39(15):941-52. PubMed ID: 12695120
[TBL] [Abstract][Full Text] [Related]
2. Design and synthesis of germline-based hemi-humanized single-chain Fv against the CD18 surface antigen.
Caldas C; Coelho VP; Rigden DJ; Neschich G; Moro AM; Brígido MM
Protein Eng; 2000 May; 13(5):353-60. PubMed ID: 10835109
[TBL] [Abstract][Full Text] [Related]
3. Guided selection of a pan carcinoma specific antibody reveals similar binding characteristics yet structural divergence between the original murine antibody and its human equivalent.
Beiboer SH; Reurs A; Roovers RC; Arends JW; Whitelegg NR; Rees AR; Hoogenboom HR
J Mol Biol; 2000 Feb; 296(3):833-49. PubMed ID: 10677285
[TBL] [Abstract][Full Text] [Related]
4. Humanization of 60.3, an anti-CD18 antibody; importance of the L2 loop.
Hsiao KC; Bajorath J; Harris LJ
Protein Eng; 1994 Jun; 7(6):815-22. PubMed ID: 7937713
[TBL] [Abstract][Full Text] [Related]
5. Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues.
Wu H; Nie Y; Huse WD; Watkins JD
J Mol Biol; 1999 Nov; 294(1):151-62. PubMed ID: 10556035
[TBL] [Abstract][Full Text] [Related]
6. Optimal humanization of 1B4, an anti-CD18 murine monoclonal antibody, is achieved by correct choice of human V-region framework sequences.
Singer II; Kawka DW; DeMartino JA; Daugherty BL; Elliston KO; Alves K; Bush BL; Cameron PM; Cuca GC; Davies P
J Immunol; 1993 Apr; 150(7):2844-57. PubMed ID: 8095956
[TBL] [Abstract][Full Text] [Related]
7. Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity.
Mateo C; Moreno E; Amour K; Lombardero J; Harris W; Pérez R
Immunotechnology; 1997 Mar; 3(1):71-81. PubMed ID: 9154469
[TBL] [Abstract][Full Text] [Related]
8. Vernier zone residue 4 of mouse subgroup II kappa light chains is a critical determinant for antigen recognition.
de Haard H; Kazemier B; van der Bent A; Oudshoorn P; Boender P; Arends JW; van Gemen B
Immunotechnology; 1999 Mar; 4(3-4):203-15. PubMed ID: 10231090
[TBL] [Abstract][Full Text] [Related]
9. Humanization by variable domain resurfacing and grafting on a human IgG4, using a new approach for determination of non-human like surface accessible framework residues based on homology modelling of variable domains.
Staelens S; Desmet J; Ngo TH; Vauterin S; Pareyn I; Barbeaux P; Van Rompaey I; Stassen JM; Deckmyn H; Vanhoorelbeke K
Mol Immunol; 2006 Mar; 43(8):1243-57. PubMed ID: 16118019
[TBL] [Abstract][Full Text] [Related]
10. A single backmutation in the human kIV framework of a previously unsuccessfully humanized antibody restores the binding activity and increases the secretion in cos cells.
Saldanha JW; Martin AC; Léger OJ
Mol Immunol; 1999 Aug; 36(11-12):709-19. PubMed ID: 10593510
[TBL] [Abstract][Full Text] [Related]
11. Humanization of mouse ONS-M21 antibody with the aid of hybrid variable regions.
Ohtomo T; Tsuchiya M; Sato K; Shimizu K; Moriuchi S; Miyao Y; Akimoto T; Akamatsu K; Hayakawa T; Ohsugi Y
Mol Immunol; 1995 Apr; 32(6):407-16. PubMed ID: 7753049
[TBL] [Abstract][Full Text] [Related]
12. Humanization of a highly stable single-chain antibody by structure-based antigen-binding site grafting.
Villani ME; Morea V; Consalvi V; Chiaraluce R; Desiderio A; Benvenuto E; Donini M
Mol Immunol; 2008 May; 45(9):2474-85. PubMed ID: 18313757
[TBL] [Abstract][Full Text] [Related]
13. A V kappa-J kappa junctional change in an antidigoxin recombinant antibody destroys digoxin-binding activity.
Hudson NW; Bruccoleri RE; Steinrauf LK; Hamilton JA; Mudgett-Hunter M; Margolies MN
J Immunol; 1990 Oct; 145(8):2718-24. PubMed ID: 2120338
[TBL] [Abstract][Full Text] [Related]
14. Human antibody derivatives against the fibroblast activation protein for tumor stroma targeting of carcinomas.
Mersmann M; Schmidt A; Rippmann JF; Wüest T; Brocks B; Rettig WJ; Garin-Chesa P; Pfizenmaier K; Moosmayer D
Int J Cancer; 2001 Apr; 92(2):240-8. PubMed ID: 11291052
[TBL] [Abstract][Full Text] [Related]
15. Humanization of an anti-human IL-6 mouse monoclonal antibody glycosylated in its heavy chain variable region.
Sato K; Ohtomo T; Hirata Y; Saito H; Matsuura T; Akimoto T; Akamatsu K; Koishihara Y; Ohsugi Y; Tsuchiya M
Hum Antibodies Hybridomas; 1996; 7(4):175-83. PubMed ID: 9140729
[TBL] [Abstract][Full Text] [Related]
16. Humanization of high affinity anti-HBs antibody by using human consensus sequence and modification of selected minimal positional template and packing residues.
Tiwari A; Khanna N; Acharya SK; Sinha S
Vaccine; 2009 Apr; 27(17):2356-66. PubMed ID: 19428851
[TBL] [Abstract][Full Text] [Related]
17. Structural correspondences between mouse and human immunoglobulin VH genes. Application to the humanization of mouse monoclonal antibodies.
Poul MA; Lefranc MP
Ann N Y Acad Sci; 1995 Sep; 764():359-61. PubMed ID: 7486546
[No Abstract] [Full Text] [Related]
18. Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation.
Kettleborough CA; Saldanha J; Heath VJ; Morrison CJ; Bendig MM
Protein Eng; 1991 Oct; 4(7):773-83. PubMed ID: 1798701
[TBL] [Abstract][Full Text] [Related]
19. Cloning of cDNAs encoding the variable domains of antibody BrE-3 and construction of a chimeric antibody.
Couto JR; Blank EW; Peterson JA; Ceriani RL
Hybridoma; 1993 Feb; 12(1):15-23. PubMed ID: 8454302
[TBL] [Abstract][Full Text] [Related]
20. Humanization of a phosphothreonine peptide-specific chicken antibody by combinatorial library optimization of the phosphoepitope-binding motif.
Baek DS; Kim YS
Biochem Biophys Res Commun; 2015 Jul; 463(3):414-20. PubMed ID: 26036575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
